Neurogene Defends ICV Delivery Choice for Rett Syndrome Gene Therapy
Event summary
- Neurogene to present data on ICV delivery for Rett syndrome gene therapy at ASGCT Annual Meeting May 12, 2026
- Preclinical results show ICV administration achieves broader brain biodistribution than intrathecal-lumbar approach
- Phase 1/2 trial data (as of October 30, 2025) demonstrate durable developmental milestone gains with NGN-401 at 1E15 vg dose
- NGN-401 has received multiple regulatory designations including FDA Breakthrough Therapy and RMAT status
The big picture
Neurogene's defense of its ICV delivery method comes as CNS-targeted gene therapies face increasing scrutiny over optimal administration routes. The company is positioning itself as a leader in purpose-built genetic medicines for rare neurological diseases, with NGN-401 potentially becoming the first approved gene therapy delivering the full-length MECP2 gene for Rett syndrome. The strategic choice of ICV administration represents a deliberate effort to maximize therapeutic efficacy while navigating regulatory pathways that favor innovative approaches to devastating neurological conditions.
What we're watching
- Clinical Validation
- Whether the ICV delivery data presented at ASGCT will convince skeptics of its superiority for CNS gene therapies.
- Regulatory Pathway
- The pace at which Neurogene advances NGN-401 through its Embolden registrational trial with FDA Breakthrough Therapy designation.
- Competitive Positioning
- How Neurogene's EXACT technology and ICV delivery approach differentiate it from other Rett syndrome gene therapy candidates.
Our editorial coverage:
Related topics